MedTrace Logo

Seaweed Extract Supplementation and Metabolic Biomarkers

NCT03853343 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-03-02

No results posted yet for this study

Summary

Double blinded, randomized, placebo controlled preliminary pilot exploratory investigation into the effects of brown seaweed extract supplementation, on fasting blood Insulin, fasting blood glucose, insulin sensitivity, blood inflammatory markers and tolerance in healthy overweight adults.

Conditions

  • Metabolic Syndrome
  • Insulin Sensitivity

Interventions

DIETARY_SUPPLEMENT

Seaweed extract

1 capsule 3 times per day

DIETARY_SUPPLEMENT

Placebo

1 capsule 3 times per day

Sponsors & Collaborators

  • University of Roehampton

    collaborator OTHER

  • BioAtlantis Ltd.

    lead INDUSTRY

Principal Investigators

  • George Tzortzis · BioAtlantis Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2020-01-30
Completion
2022-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03853343 on ClinicalTrials.gov